Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Many individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease, according to Weill Cornell Medicine researchers.
Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell Medicine.
Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine.
A preclinical trial has identified a way to thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs’ ability to relieve pain.
Inhibiting an immune signaling protein may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, a new study suggests.
A fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators.
The new injectable weight-loss drug reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo.
